Randomised placebo-controlled trial of intravenous methylprednisolone in relapsed multiple sclerosis patients without the need for ranitidine cover

Completed (inferred)Not a drug-phase studyMS (type not specified)ISRCTN46231139

What it found

No results found

We found no results in the registry or in papers.

This trial finished 21 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Methylprednisolone

    Glucocorticoid receptor agonist

  • Ranitidine

    Histamine H2 receptor antagonist

What it measured

Main measures

  • Between group differences in the absolute number of those who develop gastro-intestinal symptoms.

Other measures (1)

  • The number of those who develop gastro-intestinal symptoms who on clinical grounds require further investigation of their gastric mucosa for a possible ulcer or erosions in the 3, 6 and 12 months follow up durations.

Who could take part

MS (type not specified)

Show the full criteria

Inclusion criteria

Inclusion: Sixty matched patients from those admitted for intravenous methylprednisolone treatment for their relapsed multiple sclerosis. Exclusion: Not provided at time of registration

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Not provided at time of registration

Loading reviews and guidelines…

Related trials

History

    1. Started

      Jul 2003

    2. Finished

      Nov 2004

    Assembled by software from public sources.